MGMT promoter methylation and survival following chemotherapy for WHO grade 4 IDH-mutant astrocytoma.
作者信息
Lim-Fat Mary Jane, Wen Patrick Y, Touat Mehdi, Puduvalli Vinay K, Iorgulescu J Bryan
机构信息
Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
出版信息
Neuro Oncol. 2024 Dec 5;26(12):2388-2390. doi: 10.1093/neuonc/noae157.
Abstract
摘要
相似文献
1
MGMT promoter methylation and survival following chemotherapy for WHO grade 4 IDH-mutant astrocytoma.MGMT启动子甲基化与世界卫生组织4级异柠檬酸脱氢酶（IDH）突变型星形细胞瘤化疗后的生存情况
Neuro Oncol. 2024 Dec 5;26(12):2388-2390. doi: 10.1093/neuonc/noae157.
2
The interplay mechanism between IDH mutation, MGMT-promoter methylation, and PRMT5 activity in the progression of grade 4 astrocytoma: unraveling the complex triad theory.IDH 突变、MGMT 启动子甲基化和 PRMT5 活性在 4 级星形细胞瘤进展中的相互作用机制：揭开复杂三联体理论的面纱。
Oncol Res. 2024 May 23;32(6):1037-1045. doi: 10.32604/or.2024.051112. eCollection 2024.
3
Association of MGMT Promoter Methylation With Survival in Low-grade and Anaplastic Gliomas After Alkylating Chemotherapy.MGMT 启动子甲基化与烷化化疗后低级别和间变性神经胶质瘤生存的相关性。
JAMA Oncol. 2023 Jul 1;9(7):919-927. doi: 10.1001/jamaoncol.2023.0990.
4
Radio-chemotherapy improves survival in IDH-mutant, 1p/19q non-codeleted secondary high-grade astrocytoma patients.放化疗可提高异柠檬酸脱氢酶（IDH）突变、1p/19q未共缺失的继发性高级别星形细胞瘤患者的生存率。
J Neurooncol. 2015 Sep;124(2):197-205. doi: 10.1007/s11060-015-1822-1. Epub 2015 Jun 2.
5
Comprehensive Molecular Analysis in NRG Oncology/RTOG 9813: A Phase 3 Study of Radiation and Temozolomide Versus Radiation and BCNU/CCNU in Anaplastic Astrocytoma.NRG肿瘤学/RTOG 9813中的综合分子分析：一项关于间变性星形细胞瘤放疗联合替莫唑胺与放疗联合卡氮芥/洛莫司汀的3期研究
Int J Radiat Oncol Biol Phys. 2025 Sep 1;123(1):84-92. doi: 10.1016/j.ijrobp.2025.03.043. Epub 2025 Mar 29.
6
The role of extent of resection, chemoradiation, and MGMT promoter methylation in overall survival in a large cohort of IDH-wildtype glioblastoma.在一大群异柠檬酸脱氢酶野生型胶质母细胞瘤患者中，手术切除范围、放化疗及O6-甲基鸟嘌呤-DNA甲基转移酶（MGMT）启动子甲基化对总生存期的作用
Neurosurg Focus. 2025 Aug 1;59(2):E9. doi: 10.3171/2025.5.FOCUS25350.
7
Prediction of Ki-67 labeling index, ATRX mutation, and MGMT promoter methylation status in IDH-mutant astrocytoma by morphological MRI, SWI, DWI, and DSC-PWI.基于形态学 MRI、SWI、DWI 和 DSC-PWI 预测 IDH 突变型星形细胞瘤的 Ki-67 标记指数、 ATRX 突变和 MGMT 启动子甲基化状态。
Eur Radiol. 2023 Oct;33(10):7003-7014. doi: 10.1007/s00330-023-09695-w. Epub 2023 May 3.
8
Molecular landscape of IDH-mutant primary astrocytoma Grade IV/glioblastomas.IDH 突变型原发性星型细胞瘤 IV 级/胶质母细胞瘤的分子图谱。
Mod Pathol. 2021 Jul;34(7):1245-1260. doi: 10.1038/s41379-021-00778-x. Epub 2021 Mar 10.
9
Extent and prognostic value of MGMT promotor methylation in glioma WHO grade II.胶质母细胞瘤二级中 MGMT 启动子甲基化的程度和预后价值。
Sci Rep. 2020 Nov 12;10(1):19758. doi: 10.1038/s41598-020-76312-x.
10
MGMT methylation and its prognostic significance in inoperable IDH-wildtype glioblastoma: the MGMT-GBM study.MGMT 甲基化及其在不可切除 IDH 野生型胶质母细胞瘤中的预后意义：MGMT-GBM 研究。
Acta Neurochir (Wien). 2024 Oct 5;166(1):394. doi: 10.1007/s00701-024-06300-x.
引用本文的文献
1
Clinical value of the promoter methylation score in IDHmt low-grade glioma for predicting benefit from temozolomide treatment.异柠檬酸脱氢酶（IDH）突变型低级别胶质瘤中启动子甲基化评分对预测替莫唑胺治疗获益的临床价值
Neurooncol Adv. 2024 Dec 19;7(1):vdae224. doi: 10.1093/noajnl/vdae224. eCollection 2025 Jan-Dec.
本文引用的文献
1
The predictive value of partial promoter methylation for IDH-wild-type glioblastoma patients.部分启动子甲基化对异柠檬酸脱氢酶野生型胶质母细胞瘤患者的预测价值。
Neurooncol Pract. 2022 Sep 10;10(2):126-131. doi: 10.1093/nop/npac070. eCollection 2023 Apr.
2
Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.异柠檬酸脱氢酶（IDH）突变型脑胶质瘤：神经肿瘤学会（SNO）关于诊断、管理和未来方向的共识综述。
Neuro Oncol. 2023 Jan 5;25(1):4-25. doi: 10.1093/neuonc/noac207.
3
National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States.美国分子定义弥漫性神经胶质瘤类型的全国水平总生存模式。
Neuro Oncol. 2023 Apr 6;25(4):799-807. doi: 10.1093/neuonc/noac198.
4
Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States.分子生物标志物定义的脑肿瘤：美国的流行病学、有效性和完整性。
Neuro Oncol. 2022 Nov 2;24(11):1989-2000. doi: 10.1093/neuonc/noac113.
5
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood.EANO 成人弥漫性胶质瘤诊断与治疗指南。
Nat Rev Clin Oncol. 2021 Mar;18(3):170-186. doi: 10.1038/s41571-020-00447-z. Epub 2020 Dec 8.
Zotero 插件